The chemotherapeutic agent Doxorubicin, like several other similar anti-cancer drugs, induces senescence in human APC as well as in differentiated cells with increased γH2AX, p21, ZMAT3 and cyclin D1 while the adipogenic markers PPARγ, adiponectin and fatty acid binding protein 4 (FABP4) are decreased as markers of de-differentiation of the cells (Gustafson et al. 2022). The gene discussed is FABP4; the disease is cancer.